Opioid and Methamphetamine Use Disorders: Diagnosis and Treatment

Objectives



- 1. Review the diagnostic criteria for substance use disorders
- 2. Review office-based medications to treat opioid use disorder
- 3. Discuss interventions to treat methamphetamine use disorder


DSM 5



Diagnostic and Statistical Manual of Mental Disorders

11 criteria

Craving/Compulsion/Consequences/Loss of Control



DSM 5: Substance Use Disorder




Taking in larger amounts or for longer than intended



Unsuccessful efforts to cut down



Spending a lot of time obtaining the substance



Craving or a strong desire to use the substance

DSM 5: Substance Use Disorder




Continued use despite recurring social or interpersonal problems due to use



Important activities given up or reduced

Recurrent use in physically hazardous situations

Persistent / Recurrent physical or psychological difficulties from use





Recurrent use resulting in a failure to fulfill major role obligations

DSM 5: Substance Use Disorder






Withdrawal*


MANUAL OF MENTAL DISORDERS FIFTH EDITION DSM-5 AMERICAN PSYCHIATRIC ASSOCIATION

DIAGNOSTIC AND STATISTICAL

Substance Use Disorder



Substance Use Disorder



The words we use to describe our patients affects the care they receive

Substance Use Disorder

(\mathbf{y})	FR		
3m		Recovery Dialects	er.
Person	who uses		Negative Substance Abuser
Recurre	nce of Use		Relapse
Pharma	cotherapy		Medication- Assisted Treatment
	ental Drug Poisoning		Overdose
	son with a tance Use Disorder		Addict Alcoholic Opioid Addict
While sor	me negative lo	inguage is okay to use i	n mutual aid meetinas.

SOURCE: Ashford, R. D., Brown, A. M., & Curtis, B. (2018). Substance use, recovery, and linguistics: The impact of word choice on explicit and implicit bias. Drug and Alcohol Dependence, 189, 131–138

its use should be avoided in public, when advocating and in journalism.

Objectives




- 1. Review the diagnostic criteria for substance use disorders
- 2. Review office-based medications to treat opioid use disorder
- 3. Discuss interventions to treat methamphetamine use disorder

Medications for Opioid Use Disorder (MOUD)


What are they?

Methadone Buprenorphine XR- Naltrexone

Pharmacotherapy for Opioid Use Disorder



Pharmacotherapy for Opioid Use Disorder



Why do they matter now more than ever?




Fentanyl



Fentanyl





Fentanyl



High affinity and high efficacy at mu receptor

Single use has a short half-life (fast on, fast off)

Repeated use may lead to accumulation in adipose tissue, decreased renal clearance, more mu opioid receptor desensitization

Buprenorphine



Why is it so great?


It decreases opioid cravings, withdrawal, and use.



Patients taking buprenorphine are significantly more likely to engage and remain in treatment compared to those tapered off the medication.

Fiellen 2014; D'Onofrio 2017


Buprenorphine: Maintenance vs. Taper



Why is it so great?

Most importantly, people don't die

Mortality Risk during and after buprenorphine treatment



Mortality Risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. Sordo, et al. BMJ 2017.

Important to know:



- Buprenorphine is a high affinity binder at the mu opioid receptors. That means it sits tightly on the receptor.
- It will kick off anything else that's bound there
- But it is a partial agonist at the receptor. That means it doesn't activate the receptor completely.
- If it kicks a full agonist off the receptor, the difference between full agonism and partial agonism is big enough precipitated withdrawal

Available in two primary forms:



1. Buprenorphine monoproduct (Subutex)

2. Buprenorphine/Naloxone (Suboxone)

Buprenorphine/naloxone may reduce misuse

• Buprenorphine is taken sublingually



- Naloxone is absorbed in minute amounts sublingually.
- It is essentially inactive (in most people) unless injected
- Decreased risk of misuse (controversial)






N8 N8 N8 N8 N8 N8 N8 N8

New kid in town: buprenorphine XR (Sublocade)



Approved November 2017 Single injection lasts one month

Haight et al The Lancet 2019



How to administer and prescribe

"Traditional" inductions



• Instruct the patient to abstain from any opioid use for a minimum of:

- 12-16 hours for short-acting opioids
- 24 hours for sustained-release opioid medications
- 36 hours for methadone or fentanyl
- Observe and document mild to moderate withdrawal

"Traditional" inductions



Wait until patient is in mild to moderate withdrawal (which means receptors are empty)

Begin buprenorphine and titrate up, as needed, over 3-4 days



How do you know if a patient is in sufficient enough withdrawal to begin buprenorphine?

Clinical Opiate Withdrawal Scale (COWS)

Clinical Opiate Withdrawal Scale

For each item, circle the number that best describes the patient's signs or symptom. Rate on just the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to assessment, the increase pulse rate would not add to the score.

Patient's Name:	Date and Time/:	
Reason for this assessment:		
Resting Pulse Rate:beats/minute	G) Upset: over last ½ hour	
Measured after patient is sitting or lying for one minute	0 no GI symptoms	
O pulse rate 80 or below	1 stomach cramps	
1 pulse rate 81-100	Z nausea or loose stool	
2 pulse rate 101-120	3 vomiting or dianhea	
4 pulse rate greater than 120	5 Multiple episodes of diarrhea or vomiting	
Sweating: over past % hour not accounted for by room	Tremor observation of outstretched hands	
temperature or patient activity.	0 No tremor	
0 no report of chills or flushing	I tremor can be felt, but not observed	
subjective report of chills or flushing	2 slight tremor observable	
2 flushed or observable moistness on face	4 gross tremor or muscle twitching	
3 beads of sweat on brow or face		
4 sweat streaming off face		
Restlessness Observation during assessment	Yawning Observation during assessment	
0 able to sit still	0 no yawning	
I reports difficulty sitting still, but is able to do so	1 yawning once of twice during assessment	
3 frequent shifting or extraneous movements of legs/arms	2 yawning three or more times during assessment	
5 Unable to sit still for more than a few seconds	4 yawning several times/minute	
Pupil size	Anxiety or Irritability	
0 pupils pinned or normal size for room light	0 none	
I pupils possibly larger than normal for room light	I patient reports increasing irritability or anxiousness	
2 pupils moderately dilated	2 patient obviously irritable anxious	
5 pupils so dilated that only the rim of the iris is visible	4 patient so irritable or anxious that participation in the assessment is <u>difficult</u>	
Bone or Joint aches If patient was having pain	Gooseflesh skin	
previously, only the additional component attributed	0 skin is smooth	
to opiates withdrawal is scored	3 piloerrection of skin can be felt or hairs standing up	
0 not present	ON BITTINS	
1 mild diffuse discomfort	5 prominent piloerrection	
2 patient reports severe diffuse aching of joints/ muscles		
4 patient is rubbing joints or muscles and is unable to sit still because of discomfort		
Runny nose or tearing Not accounted for by cold		
symptoms or allergies		
0 not present	Total Score	
l nasal stuffiness or unusually moist eyes	The total score is the sum of all 11 items	
2 nose running or tearing	Initials of person	
4 nose constantly running or tears streaming down cheeks	completing Assessment:	

Score: 5-12 = mild; 13-24 = moderate; 25-36 = moderate is severe; more than 36 = severe withdrawal

Clinical Opiate Withdrawal Scale (COWS)

- Resting pulse rate
- Sweating/chills
- Restlessness
- Pupil size
- Bone or joint aches
- Runny nose

- Gl upset
- Tremor
- Yawning
- Anxiety or irritability
- Goose bumps
- Guides timing of first dose of buprenorphine

Traditional induction



Begin buprenorphine with COWS is 10-12

Prepare for Discomfort

- Acetaminophen and ibuprofen
- Clonidine
- Hydroxyzine
- Trazodone
- Tizanidine or Methocarbamol
- Ondansetron
- Bismuth or Loperamide

Srivastara, 2020; Kosten, 2019; Kuszmaul 2020; Kheirabadi 2008 ;Salehi 2011; Sanders 2013

Dosing Schedule

	Suggested dosing pills or heroin	Suggested dosing fentanyl
Day 1	2-4mg (wait 45 min) + 4mg if needed	8-16mg
Day 2	Day 1 dose + 4mg if needed (single dose)	16-20mg
Day 3	Day 2 dose + 4mg if needed (single dose)	20-24mg
Day 3-28	Adjust as needed	24mg

Precipitated Withdrawal

If opioid withdrawal appears shortly after the first dose buprenorphine may have precipitated a withdrawal syndrome

Precipitated Withdrawal

Greatest severity of buprenorphinerelated precipitated withdrawal in the first few hours (1-4) after a dose

Challenges with Traditional Induction

- Patient must experience withdrawal, which is difficult
- With fentanyl, sometimes need to wait even longer than 3 days because fentanyl sticks around in the fat
- Always possible that patient will experience precipitated withdrawal

Another option...



ninja clipart PNG Designed By 588ku from https://pngtree.com/freepng/sneak-attack-sneak-attack-man-inblack-black-man-ninja_3931511.html?sol=downref&id=bef

Low dose buprenorphine induction

- Many different protocols
 - Initial protocol "Bernese Method"
 - Usually start at 0.5 mg
 - Often 7-10 days
 - No universally accepted regimen
 - Can continue full agonists throughout the entire induction

Day Dose	
1	0.5 mg daily
2	0.5 mg bid
3	1 mg bid
4	2 mg bid
5 4 mg bid	
6 4 mg tid	
7 8 mg tid	

Adapted from Yale protocol

⁹Opioid Use Disorder Practice Update (2022) British Columbia Centre on Substance Use

Rapid low dose inductions

	Day	Full Opioid Agonist	Buprenorphine Dosing Instructions	Total Daily Dose of Buprenorphine
	1	Continue	0.5 mg SL once	0.5 mg
	2	Continue	0.5 mg SL bid	1 mg
	3	Continue	1 mg SL bid	2 mg
1	4	Continue	2 mg SL bid	4 mg
	5	STOP (if able to tolerate increase)	4 mg SL once. If tolerated take additional 4 mg in 10 mins. Continue to titrate prn for ongoing cravings or withdrawal symptoms for TDD	16-24 mg

Tips and Tricks

Good patient instructions are helpful. Consider visual aids









Tab: 2 mg

You can micro-dose with

Suboxone or Subutex.

Personal Plan	Dose	Stop Heroin Day	Notes
Dav			
Day			
Dev			

Standard Plan	Dose	Stop Herain Day	Notes
Day 1	0.5		
Day 2	0.5+0.5		
Day 3	1+1		
Day 4	2+2		
Day 5	3+3		
Day 6	4+4	ж	
Day 7	8+4+4		

Tips and Tricks

- Specifically outline what adjunct meds you are giving and for what
- Instruct patients to take AM buprenorphine before their full agonist

Tips and Tricks

- Close follow up
- Modify or slow protocol as needed (i.e. repeat days)
- Give naloxone to every patient

Maintenance



- Continue patient at the dose at which they have no withdrawal symptoms and minimal to no cravings
- The maximum effective dose has long been considered 24mg
- However, with fentanyl, many patients continue to have cravings and withdrawal symptoms at typical doses (16-24 mg)
- It is becoming more common to up titrate to 28-32 mg which seems to be helpful for some patients

Regulations and Regulatory Changes




Buprenorphine approved by the FDA in 2002. Prescribers were required to undergo an 8 -our training, register with the DEA, obtain an "X-waiver" and could only prescribe to 30 patients at a time


2016 NPs and PAs were allowed to prescribe, but with a longer training requirement. Still required to obtain X waiver and register with the DEA and limit patients

Training requirement removed in 2021, though prescribers still needed to obtain the waiver and register with the DEA

Jan 2023 all buprenorphine specific DEA requirements were removed

Naltrexone for Extended Release Injectable Suspension





Outcome	XR-NXT (n=283)	BUP-NX (n-287)	Treatment Effect
Inducted to study medication (ITT)	204 (72%)	270 (94%)	OR 0.16, 0.09-0.28; P<0.0001
Relapse-free survival (weeks)	8.4 (3-23.4)	14.4 (5.1-23.4)	HR 1.36, 1.10-1.68;
Sur mon (meens)	20.4 (5.4-23.4)	15.2 (5.7-23.4)	HR 0.92, 0.71-1.18 p=0.49
Opioid relapse, weeks 3-24	185 (65%)	163 (57%)	OR 1.44, 1.02-2.01; p=0.036
	106/204 (52%)	150/270 (56%)	OR 0.87, 0.60-1.25 p=0.44
Lee JD, et	al. <i>Lancet</i> 2017		

Difficult to start

Requires abstinence from opioids 4 – 7 days

About 25% of patients will not complete induction



Outcome	XR-NXT (n=283)	BUP-NX (n-287)	Treatment Effect
Inducted to study medication (ITT)	204 (72%)	270 (94%)	OR 0.16, 0.09-0.28; P<0.0001
Relapse-free survival (weeks)	8.4 (3-23.4)	14.4 (5.1-23.4)	HR 1.36, 1.10-1.68; p=0.0040
	20.4 (5.4-23.4)	15.2 (5.7-23.4)	HR 0.92, 0.71-1.18, p=0.49
Opioid relapse, weeks 3-24	185 (65%)	163 (57%)	OR 1.44, 1.02-2.01; p=0.036
	106/204 (52%)	150/270 (56%)	OR 0.87, 0.60-1.25; p=0.44

Lee JD, et al. Lancet 2017

Overdose data

- Original findings
 - more overdoses in the XR-NTX arm, but not statistically significant
- Re-analysis
 - Researchers had missed cases of overdose
 - 28 overdoses in XR-NTX arm
 - 2.4 x greater hazard of overdose compared to bup/nal

Summary

- Opioid use disorder can be treated in an outpatient setting
- Buprenorphine saves lives
- Please prescribe

Objectives



- 1. Review the diagnostic criteria for substance use disorders
- 2. Review office-based medications to treat opioid use disorder
- 3. Discuss interventions to treat methamphetamine use disorder

Methamphetamine Use Disorder



- Form of dmethamphetamine
- Closely related to amphetamine
- Longer lasting and more toxic to the CNS














Materials:


1 2 Liter Bottle (with cap)
1 1 Liter Bottle (get 2 caps for it)
1 20 oz. Bottle (with cap)
1 Quart Jar
2 ft. 1/4in. diameter rubber/plastic hose (aquarium hose works good)
Coffee Filters
1 Funnel
1 Tubing Cutter (go to Home Depot)
2 Plyers
1 Roll of Ductape or Electrical Tape 1 Blender or Food Processor
200 60mg Pseudophedrine HCL pills (Actifed, Sudafed, Suphedrine, etc.)
1 1/2 cups Ammonium Nitrate fertilizer (33-0-0)
3 cans starting fluid
3 AA Energizer Lithuim Batteries

bottle Red Devil brand Lye

2 caps of water (use the top off the 2 liter) 1 box Iodized Salt 1 bottle Liquid Fire brand drain opener

Procedure:

 Rinse and dry out all of your bottles. Be sure to get ALL of the moisture out. Don't go any further until they are completely dry.
 Put your pills into the blender or food processor and grind them into powder. Mix them in with the 1 1/2 cups of Ammoniun Nitrate fertilizer. Use the funnel to pour the mixture into the 2 liter



2005: CMEA (Combat Methamphetamine Epidemic Act)




Result?




In Oregon, from 2004 to 2011, methamphetamine lab incidents decreased from an average of 24 per month to less than one per month


And Yet...






Increase dopamine to +/- 200 times basal output







Medical Issues Related to Methamphetamine Use



Neurotoxicity, cognitive effects

- Excessive DA damaging cell structures
- Disruption of blood-barrier
- Use associated with poorer performance on motor and processing tasks, visual and verbal fluency
- More than 2/3 of those with MUD show cognitive impairment
- May limit ability to follow through with treatment, understand advice, and achieve treatment outcomes

Medical Issues Related to Methamphetamine Use

Cardiovascular and cerebrovascular

- Leading cause of death with MUD
- Strokes more common in young men (hemorrhagic)
- Also associated with pulmonary htn, cardiac arrhythmia, cardiomyopathy

Lappin et al., 2017

Two evidence-based behavioral interventions: contingency management and harm reduction

Drug and Alcohol Dependence 212 (2020) 108060



Review

Non-pharmacological interventions for methamphetamine use disorder: a systematic review

PV AshaRani*, Aditi Hombali, Esmond Seow, Wei Jie Ong, Jit Hui Tan, Mythily Subramaniam

ABSTRACT

Research Division, Institute of Mental Health, 10 Buangkok View, Singapore

ARTICLE INFO

Keywords: Methamphetamine Methamphetamine use disorder Non-pharmacological interventions abstinence

Background: Methamphetamine (METH) use is on the rise globally, with the number of treatment seekers increasing exponentially across the globe. Evidence-based therapies are needed to meet rising treatment needs. This systematic review intends to appraise the existing evidence to identify effective non-pharmaceutical approaches for the treatment of METH use disorder.

Methods: Five electronic bibliographic databases-Ovid (Medline), Embase, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Web of Science and PsycINFO- were searched to identify relevant studies that were published between January 1995 to February 2020. Studies were selected and assessed by two independent reviewers. A systematic review of data from both randomised control trials (RCT) and non-RCTs was conducted to appraise the evidence.

Results: A total of 44 studies were included in the review. Behavioural interventions, i.e. cognitive behavioural therapy (CBT), contingency management (CM), exercise, residential rehabilitation based therapies, repetitive transcranial magnetic stimulation (rTMS), and matrix model demonstrated treatment efficacy in promoting abstinence, reducing methamphetamine use or craving in the participants. While CM interventions showed the strongest evidence favouring the outcomes assessed, tailored CBT alone or with CM was also effective in the target population.

Conclusions: Behavioural interventions should be considered as the first line of treatment for methamphetamine use disorder. Future studies should address the longevity of the effects, and limitations due to smaller sample sizes and high dropout rates to enable better assessment of evidence.

1. INTRODUCTION

Illicit amphetamine use has grown steadily over the last two decades with almost 28.9 million people using amphetamine type stimulants (ATS, amphetamine, methamphetamines) in 2017 (United Nations Office on Drugs and Crime, 2019), with methamphetamine (METH) being the most frequently used and potent drug in the ATS family (Perez-mana et al., 2013). The overdose deaths involving METH tripled from 2011 to 2016 with a 29% increase per year (Hedegaard et al., 2018). METH is the fourth leading cause of drug overdose deaths in the US, accounting for 10.6% of deaths in 2016, 49.8% of which involved concomitant use of another drug(s) with heroin (21.8%), fentanyl (11.1%), and cocaine (8.3%) being the top 3 concomitant drugs . A recent cross-sectional study among a million patients showed a 486.7% increase in METH positive urine from 2013 to 2019 in the US (Twillman et al., 2020), which suggests another impending drug

epidemic.

Amphetamine abuse is often accompanied by physical (e.g., bloodborne diseases, Farrell et al., 2019) or psychological co-morbidities (Akindipe et al., 2014). Recent reports highlight the rapid increase in treatment-seeking amphetamine dependents that suggests an emerging global health challenge. In the US, amphetamine-related hospitallisation is the fourth most common drug-related hospitalisation after alcohol, opiates, and cannabis (National Admission to Substance Abuse Treatment Services, 2016). A cross-sectional study conducted using national hospital discharge data showed that amphetamine-related admissions increased steeply between 2008 to 2015 in the US. Mean inhospital mortality was higher for amphetamine abuse than for any other substance abuse. The annual hospital-related cost for amphetamine abuse increased steadily from \$436 million in 2003 to \$2.17 billion in 2015 (Winkelman et al., 2018).

Despite being the second most common illicit drug abused worldwide (United Nations Office on Drugs and Crime, 2017), no approved

* Corresponding author at: Research Division, Institute of Mental Health, 10 Buangkok View, 539747, Singapore. E-mail address: Asharani_PEZHUMMOOTTIL_VASUDEVAN_N@imh.com.sg (P. AshaRani).

https://doi.org/10.1016/j.drugalcdep.2020.108060 Received 8 January 2020; Received in revised form 4 May 2020; Accepted 5 May 2020 Available online 13 May 2020 0376-8716/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).



ABOUT BROWSE PUBLISH

PLOS MEDICINE

RESEARCH ARTICLE

Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis

Franco De Crescenzo, Marco Ciabattini, Gian Loreto D'Alò, Riccardo De Giorgi, Cinzia Del Giovane, Carolina Cassar, Luigi Janiri, Nicolas Clark, Michael Joshua Ostacher, Andrea Cipriani 🔤

Published: December 26, 2018 • https://doi.org/10.1371/journal.pmed.1002715

Article	Authors	Metrics	Comments	Media Coverage	Download	I PDF 🔫
¥					Print	Share
Abstract	Abstract				Check	k for updates
Author summary	Background	Background				
Introduction	-				PLOS MED	X
Methods	•		al interventions for cocaine Il unclear which intervention			
Results			e effectiveness of all availa			FOR
Discussion		one or in combination) for t mphetamine addiction.	the short- and long-term tre	atment of people with	PAPE	
Supporting information					Cance	
Acknowledgments	Methods and	Methods and findings Advances: Clinically				
References Reader Comments (0) Media Coverage (1) Figures	structured psych the treatment of were efficacy (pr (proportion of pa measured the ad the interventions mean differences effects. The risk strength of evide Evaluation (GRA (PRISMA-NMA) 42017042900). V participants. The contingency mar intervention that 95% CI 1.24–6.5 and at longest fo	osocial intervention agains cocaine and/or amphetam oportion of patients in abs tients who dropped out du ute (12 weeks) and long-t and the longest duration x were estimated using pa of bias of the included stu nce with the Grading of R DE) approach. We followe guidelines, and the protoc Ve included 50 RCTs eval strength of evidence rang agement (CM) plus comm increased the number of a 1, $P = 0.013$), and also at llow-up (OR 3.08, 95% CI	andomised controlled trials st an active control or treat ine addiction in adults. Prir tinence, assessed by urina e to any cause) at the end erm (longest duration of stu- of abstinence. Odds ratios invise and network meta-ai dies was assessed with the ecommendations Assessme ad the PRISMA for Network- ol was registered in PROS uating 12 psychosocial inte- ged from high to very low. Co- hunity reinforcement approx abstinent patients at the en- 12 weeks (OR 7.60, 95% of 1.33–7.17, $P = 0.008$). At ard the highest number of st	ment as usual (TAU) for nary outcome measures lysis) and acceptability of treatment, but we also udy follow-up) effects of (ORs) and standardised nalysis with random o Cochrane tool, and the ent, Development and the Meta-Analyses PERO (CRD riventions or TAU in 6,942 compared to TAU, ach was the only d of treatment (OR 2.84, CI 2.03–28.37, <i>P</i> = 0.002) the end of treatment, CM	Applic Insigh Early Detect and M Residu Diseas	able ts into tion inimal Jal

0	24
Save	Citation
11,720	0
_{View}	Share

SEARCH



Q

advanced search



- Behavioral interventions = first line treatment for MUD
- Most behavioral interventions (CBT, MI, Matrix model, exercise, CM) demonstrated some efficacy in reducing methamphetamine cravings and use
- Contingency management most consistently showed reduced use, increased retention in treatment, better quality of life

Asharani et al Drug and Alcohol Dependence 2020 De Crescenzo et al PLOS Medicine 2018



Photo courtesy of John Mahan MD

Contingency Management: Theory



- Addiction is sustained through reinforced learning
- We cannot simply unlearn habits we must learn new and competing habits
- CM entrains new behaviors that support the process of recovery
- Breaks recovery process down into a series of concrete, attainable goals
- > 100 RCTs affirm the effectiveness of CM in treating addiction

Roll JM et al. Am Jnl Psych 2006 Roll JM et al. Addict Behav 2013 Rawson, RA et al. Addiction 2016

Contingency Management: Practice



- 1. Identify a target behavior that can be objectively measured, attainable, and reinforced in real time.
- 2. Reward that behavior immediately when it occurs, using rewards that are valuable to participants (but not necessarily expensive).
- 3. Use an escalating schedule of reinforcement.



Photo courtesy of John Mahan MD

Example



Patient on long term IV antibiotics who is often not in her room when it is time for her antibiotics. She likes chocolate and Starbuck's Frappuccinos

Target behavior: be in the room 8:00 am, noon, and 5 pm

Reward: Hershey's kiss each time she is in the room when the nurse arrives with antibiotics

Escalating schedule: \$5 Starbuck's card after she has accumulated 10 Hershey's kisses

Center for Substance Abuse Treatment. *Substance Abuse: Clinical Issues in Intensive Outpatient Treatment.* Treatment Improvement Protocol (TIP) Series 47.

Harm Reduction



Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use. Harm Reduction is also a movement for social justice built on a belief in, and respect for, the rights of people who use drugs.

Harm Reduction is also



Part of the continuum of care

Relationship building

Treatment

Harm Reduction is not



What we do when nothing else works

Harm Reduction Practices: Methamphetamines

Safe injecting:



- Clean needles/rigs (including don't share filters, cookers)
- Don't use alone
- Use needles bevel up
- Use a filter whenever possible
- Test for fentanyl
- Clean water

Collins S et al. Intl Jnl of Drug Policy 2019 Thakarar K, Weinstein ZM, Walley AY. *Postgrad Med J*. 2016;92(1088):356–363.

Harm Reduction Practices: Methamphetamines

Hydration

Toothbrushes

Condoms

Naloxone

Patient Centered: Ask the patient/client: what harms most concern you?

Collins S et al. Intl Jnl of Drug Policy 2019 Thakarar K, Weinstein ZM, Walley AY. *Postgrad Med J*. 2016;92(1088):356–363.

Meds for MA/A Use Disorder

- No FDA-approved meds for MA/A use disorder (MUD)
- Lots of research looking into possible treatments
- Will review published findings from 2 recent trials
- Systematic reviews of medications for MUD

Mirtazapine




- FDA-approved antidepressant
- Main side effects weight gain and somnolence
- Mixed monoamine agonist-antagonist
- Cisgender men & transgender women sex w/ men
- Double blind RCT of 120 participants
- 1 in methamphetamine + UDT despite low adherence

Naltrexone IM + Bupropion



- Large multi-center RCT, two-stage, sequential parallel comparison design.
- Number needed to treat 9, low treatment improvement



Sufficient Evidence of No Benefit




• Dopamine agonists (levodopa, cabergoline, pramixpexole)

- Antipsychotics aripiprazole
- Antidepressants SSRIs
- Anticonvulsants/muscle relaxants
- Varenicline

Briones M et al. Drug Alcohol Depend 2018 Ronsley C et al PLoS ONE 2020 Chan B et al Addiction 2019

Insufficient Evidence of Benefit



- Prescription psychostimulant agonist therapy methylphenidate, modafinil, lisdexamphetamine, dextroamphetamine, mixed amphetamine salts
- Antidepressants non-SSRI (mirtazapine, bupropion)
- N-acetylcysteine (NAC) acts as a physiological reservoir of neuronal glutamate

Coffin P et al JAMA Psychiatry 2020 Ronsley C et al PLoS ONE 2020 Tardelli VS et al Psychopharmacology 2020 Chang C-T et al Clin Psychopharmacol Neurosci 2021



Summary

- Methamphetamine use and use disorders are escalating
- There are effective behavioral interventions
- Harm reduction is treatment
- Medications are being investigated

•Questions?

•Thoughts?